The Eye Care Blog

Researchers at the University of Bonn and Hospital Saarbrücken find Intravitreal bevacizumab a solution to choroidal neovascularization patients to secondary pseudoxanthoma elasticum. Robert P. Finger and his colleagues have tested the study to 15 patients. All these patients had active CNV secondary on pseudoxanthoma elasticum.

Patients received additional injections based on disease activity on an average of 2.4 injections, confirmed sources. Best corrected visual acuity averaged 20/100 at baseline. After the first injection, BCVA improved to average 20/63 and remained stable through final follow-up. Central retinal thickness significantly decreased, from 252 µm at baseline to 214 µm at final follow-up, the investigators reported. The study was published in the April issue of British Journal of Ophthalmology.
Source: OSN SUPER SITE

You may also like to read

• Surgical Removal Of Extensive Peripapillary Choroidal Neovascularization Proves Good In Long Run
• VEGF Trap-Eye Phase 2 trial reports significant improvement in neovascular disease
• Exposure to UV Light Can Cause Permanent Damage to Your Eyes
• Some important factors that develop Age related Macular Degeneration
• Moxifloxacin shows better result if used 2 hours before cataract surgery
• Phase-II Clinical Trial of Drug Evizon for Wet Age-Related Macular Degeneration
• Most expensive drug "Lucentis" now available through cost effective scheme by NICE
• Ocular diseases can be cured by new drug - VEGF Trap-Eye
• Laser surgery proved better than steroid injection for diabetic macular edema
• Cataract removal Operations Combining Techniques Used on Humans and Animals

This entry was posted on Thursday, May 15th, 2008 at 8:08 am. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.